Amneal Pharmaceuticals (NASDAQ:AMRX) Updates FY 2025 Earnings Guidance

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share guidance of 0.650-0.70 for the period, compared to the consensus earnings per share estimate of 0.680. The company issued revenue guidance of $3.0 billion-$3.1 billion, compared to the consensus revenue estimate of $3.0 billion.

Analyst Ratings Changes

Several research firms have recently commented on AMRX. StockNews.com raised Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Monday. Barclays boosted their price objective on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a report on Monday, March 3rd. Finally, JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and raised their target price for the company from $9.00 to $12.00 in a research note on Monday, February 24th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $11.50.

Amneal Pharmaceuticals Stock Performance

AMRX stock traded up $0.03 during midday trading on Wednesday, hitting $7.21. 686,842 shares of the company's stock were exchanged, compared to its average volume of 1,421,607. Amneal Pharmaceuticals has a one year low of $6.29 and a one year high of $9.48. The stock's fifty day moving average price is $7.98 and its 200-day moving average price is $8.15. The company has a market cap of $2.23 billion, a PE ratio of -10.60 and a beta of 1.17.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its quarterly earnings data on Friday, May 2nd. The company reported $0.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.05. The business had revenue of $695.42 million during the quarter, compared to analyst estimates of $714.78 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. On average, analysts expect that Amneal Pharmaceuticals will post 0.53 EPS for the current year.

Insider Buying and Selling

In other Amneal Pharmaceuticals news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the business's stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $8.35, for a total value of $41,750,000.00. Following the sale, the insider now owns 48,578,209 shares in the company, valued at approximately $405,628,045.15. The trade was a 9.33 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Gautam Patel sold 80,000 shares of Amneal Pharmaceuticals stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $8.90, for a total transaction of $712,000.00. Following the completion of the sale, the director now owns 1,808,886 shares in the company, valued at $16,099,085.40. This trade represents a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 26.56% of the stock is currently owned by company insiders.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.